ENMD-981693 Completed Phase 2 Trials for Triple-Negative Breast Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0068542 (Triple-Negative Breast Cancer)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT01639248	Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC	ENMD-981693 (DB16891)